In a study conducted on 47 hepatocellular cancer (HCC) patients receiving PD-1 inhibitors in combination with radio- and antiangiogenetic therapy, the identification of <2 PD-L1 positive CTCs using CytoSorter at the baseline was associated with a higher objective response rate. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.